NCT06966453 2026-03-04A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast CancerPfizerPhase 1/2 Recruiting100 enrolled
NCT06378242 2024-07-11To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2RemeGen Co., Ltd.Phase 1/2 Recruiting24 enrolled